Abstract
In this paper, we consider the role of the genetics of inflammation in the pathophysiology of prostate cancer (PCa). This paper is not an extensive review of the literature, rather it is an expert opinion based on data from authors’ laboratories on age-related diseases and inflammation. The aim is the detection of a risk profile that potentially allows both the early identification of individuals at risk for disease and the possible discovery of potential targets for medication. In fact, a major goal of clinical research is to improve early detection of age-related diseases, cancer included, by developing tools to move diagnosis backward in disease temporal course, i.e., before the clinical manifestation of the malady, where treatment might play a decisive role in preventing or significantly retarding the manifestation of the disease. The better understanding of the function and the regulation of inflammatory pathway in PCa may help to know the mechanisms of its formation and progression, as well as to identify new targets for the refinement of new treatment such as the pharmacogenomics approach.
Similar content being viewed by others
References
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist 8:541–552
Serrano M, Blasco MA (2007) Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8:715–722
Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767–774
Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C (2008) Inflammation, ageing, and cancer. Mech Ageing Dev. (Epub ahead of print)
Derhovanessian E, Solana R, Larbi A, Pawelec G (2008) Immunity, ageing and cancer. Immun Ageing 5:11
Finn OJ (2006) Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res 36:73–82
Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1–50
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Hussain T, Gupta S, Mukhta H (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125–135
Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park) 16:217–226
Hsu PI, Lai KH, Hsu PN, Lo GH, Yu HC, Chen WC, Tsay FW, Lin HC, Tseng HH, Ger LP, Chen HC (2007) Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 102(4):102725–102730
Zisman TL, Rubin DT (2008) Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 714:266–269
Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266
Caruso C, Lio D, Cavallone L, Franceschi C (2004) Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci 1028:1–13
Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 1:3–10
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Borrello MG, Alberti L, Fischer A, Degl’innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825–14830
De Marzo AM, Coffey DS, Nelson WG (1999) New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53:29–39
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57:43–66
Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C (2008) Inflammation and prostate cancer. Future Oncol 4:637–645
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6–S11
Hochreiter WW, Nadler RB, Koch AE, Campbell PL, Ludwig M, Weidner W, Schaeffer AJ (2000) Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 56:1025–1029
Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP (2008) Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68:872–882
Franks LM (1954) Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 68:617–621
Bennett BD, Richardson PH, Gardner WA (1993) Histopathology and cytology of prostatitis. In: Lepor H, Lawson RK (eds) Prostate disease. Saunders, Philadelphia, pp 399–414
De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG (2003) Human prostate cancer precursors and pathobiology. Urology 62:55–62
Putzi MJ, De Marzo AM (2000) Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56:828–832
Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA (2001) Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 158:1767–1773
De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992
Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60:78–83
Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15:93–99
Montironi R, Mazzucchelli R, Scarpelli M (2002) Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann NY Acad Sci 963:169–184
Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL (2005) Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 173(6):1969–1974
Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, Greenberg RS, Schoenberg JB, Liff J, Schwartz AG, Hoover RN, Fraumeni JF Jr (2000) Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 82:718–725
Strickler HD, Goedert J (2001) Sexual behaviour and evidence for an infectious cause of prostate cancer. Epidemiol Rev 23:144–151
Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79
Taylor ML, Mainous AG, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37:506–512
Rosenblatt KA, Wicklund KG, Stanford JL (2001) Sexual factors and the risk of prostate cancer. Am J Epidemiol 153:1152–1158
Carruba G (2007) Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 102:899–911
Bosland MC, Ford H, Horton L (1995) Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague–Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylstilbestrol. Carcinogenesis 16:1311–1317
Candore G, Lio D, Colonna Romano G, Caruso C (2002) Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 1:29–35
Tam NN, Leav I, Ho SM (2007) Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. Am J Pathol 171:1334–1341
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269
Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE (2000) Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 44:19–25
Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ (2003) Oestrogens and prostate cancer. Endocr Relat Cancer 10:187–191
Prins GS, Huang L, Birch L, Pu Y (2006) The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci 1089:1–13
Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP (2004) Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 89:2434–2441
Bulun SE, Simpson ER (2008) Aromatase expression in women’s cancers. Adv Exp Med Biol 630:112–312
Risbridger GP, Ellem SJ, McPherson SJ (2007) Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 39:183–188
Bianco JJ, McPherson SJ, Wang H, Prins GS, Risbridger GP (2006) Transient neonatal exposure to estrogen-deficient mice (Aromatase knockout) reduces prostate weight and induces inflammation in late life. Am J Pathol 168:1869–1878
Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, Krishan A, Mohan H, Kaur P (2008) Hormone receptor-related gene polymorphisms and prostate cancer risk in north Indian population. Mol Cell Biochem 314:25–35
Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, Fournier G, Valeri A, Larre S, Thibault F, Giordanella JP, Pouchard M, Zheng Y, Hamdy FC, Cox A, Cancel-Tassin G (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 25:3596–3602
Huang YC, Chen M, Lin MW, Chung MY, Chang YH, Huang WJ, Wu TT, Hsu JM, Yang S, Chen YM (2007) CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology 69:996–1000
Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamoto T, Mitsumori K, Ichikawa T, Ogawa O, Nakamura A, Habuchi T (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 124:1982–1989
Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096
Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 192:1130–1137
Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55:27–36
Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H (2003) Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 198:1411–1416
Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, Ichikawa T, Tsukino H, Qiu D, Katoh T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24:2431–2437
Mononen N, Seppälä EH, Duggal P, Autio V, Ikonen T, Ellonen P, Saharinen J, Saarela J, Vihinen M, Tammela TL, Kallioniemi O, Bailey-Wilson JE, Schleutker J (2006) Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 66:743–747
Li L, Cicek MS, Casey G, Witte JS (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2280–2281
Candore G, Balistreri CR, Grimaldi MP, Listì F, Vasto S, Chiappelli M, Licastro F, Colonna-Romano G, Lio D, Caruso C (2007) Polymorphisms of pro-inflammatory genes and Alzheimer’s disease risk: a pharmacogenomic approach. Mech Ageing Dev 128:67–75
Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CT, Vasto S, Scafidi V, Caruso C, Candore G (2008) Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 14:2678–2685
Vane JR, Bakhle YS, Botting RM (1998) Cyclooxigenase 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120
Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157–33160
Taketo MM (1998) COX-2 and colon cancer. Inflamm Res 47:S112–S116
Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A (2002) Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53:232–240
Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A, Bartlett JM (2004) Her2 and COX2 expression in human prostate cancer. Eur J Cancer 40:50–55
Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Cassinello Espinosa J, Antón Aparicio LM (2007) Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol 9:694–702
Wang W, Bergh A, Damber JE (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61:60–72
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073
Lin DW, Nelson PS (2003) The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2:119–126
Basler JW, Piazza GA (2004) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171:S59–S62
Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96–102
Singh A, Purohit A, Ghilchik MW, Reed MJ (1999) The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6:139–147
Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739–5742
Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27–35
Frasor J, Weaver AE, Pradhan M, Mehta K (2008) Synergistic upregulation of prostaglandin E synthase expression in breast cancer cells by 17b-estradiol and pro-inflammatory cytokines. Endocrinology 149(12):6272–6279
Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299:468–476
Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25:961–966
Shahedi K, Lindström S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Bälter K, Chang BL, Adami HO, Liu W, Grönberg H, Xu J (2006) Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119:668–672
Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, Shahedi K, Xu J, Adami HO, Grönberg H, Bälter KA (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120:398–405
Chen YQ, Duniec ZM, Liu B, Hagmann W, Gao X, Shimoji K, Marnett LJ, Johnson CR, Honn KV (1994) Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 54:1574–1579
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8:467–483
Ghosh J, Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 95:13182–13187
Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H (2001) Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91:737–743
Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C, IMUSCE (2008) The extreme longevity: the state of the art in Italy. Exp Gerontol 43:45–52
Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:3–10
Uematsu S, Akira S (2008) Toll-like receptors (TLRs) and their ligands. Handb Exp Pharmacol 183:1–20
Tsan MF, Gao B (2004) Endogenous ligands of Toll-like receptors. J Leukoc Biol 76:514–519
Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listì F, Vasto S, Lio D, Caruso C, Candore G (2008) Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer’s disease. Curr Pharm Des 14:2672–2677
Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M, Hoffmann E, Franceschi C, Caruso C (2004) Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA 292:2339–2340
Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13:460–469
Tsan MF (2006) Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16:32–37
Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G (2008) Cancers take their toll: the function and regulation of Toll-like receptors in cancer cells. Oncogene 27:225–233
Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7:1271–1285
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759
Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014
Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, Mayer L, Unkeless J, Li D, Yuan Y, Zhang GM, Xiong H, Feng ZH (2007) Listeria monocytogenes promote tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res 67:4346–4352
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859–3868
Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349:366–381
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296
Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H (2004) Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 64:2918–2922
Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ (2005) Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 65:11771–11778
Cheng I, Plummer SJ, Casey G, Witte JS (2007) Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:352–355
Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H (2005) Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 97:525–532
Chen YC, Giovannucci E, Kraft P, Lazarus R, Hunter DJ (2007) Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev 16:1982–1989
Stevens VL, Hsing AW, Talbot JT, Zheng SL, Sun J, Chen J, Thun MJ, Xu J, Calle EE, Rodriguez C (2008) Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer. 123(11):2644–2650
Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202–1216
Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316:701–705
Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGF-beta signalling and its roles in progression of tumors. Cancer Sci 94:230–234
Brattain MG, Howell G, Sun LZ, Willson JK (1994) Growth factor balance and tumor progression. Curr Opin Oncol 6:77–81
Fynan TM, Reiss M (1993) Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 4:493–540
Cambien F, Ricard S, Troesch A, Mallet C, Générénaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O (1996) Polymorphisms of the transforming growth factor beta 1 gene in relation to myocardial infarction and blood pressure. Hypertension 28:881–887
Randall LL, Hardy SJ (1989) Unity in function in the absence of consensus in sequence: role of leader peptides in export. Science 243:1156–1159
Faria PC, Saba K, Freitas Neves A, Cordeiro ER, Marangoni K, Garcia Freitas D, Goulart LR (2007) Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients. Cancer Invest 25:726–732
Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27–55
Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8:1314–1325
Giri D, Ittmann M (2000) Interleukin-1β is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 157:249–255
Castro P, Giri D, Lamb D, Ittmann M (2003) Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 55:30–38
Ricote M, García-Tuñón I, Bethencourt FR, Fraile B, Paniagua R, Royuela M (2004) Interleukin-1 (IL-1α and IL-1β) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 7:1388–1396
Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK (2008) Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology 71:868–872
Cheng I, Krumroy LM, Plummer SJ, Casey G, Witte JS (2007) MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:1309–1311
Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Grönberg H, Xu J (2005) Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93:493–497
Liu Y, Lin N, Huang L, Xu Q, Pang G (2007) Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 26:613–618
Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112:146–152
Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, Ichikawa N, Kotake S, Tanaka M, Hara M, Kamatani N (2002) Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun 3:394–399
Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154:1503–1512
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 174:1209–1220
Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5:189–196
Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, Pummer K, Kapp KS (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43:472–475
Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19:119–124
McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372
Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66:4525–4530
Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA (2006) Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev 15:249–253
Zabaleta J, Lin H-Y, Sierra RA, Hall CM, Clark PE, Sartor OA, Hu JJ, Ochoa AC (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 29:573–578
Vaday GG, Peehl DM, Kadam PA, Lawrence DM (2006) Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66:124–134
König JE, Senge T, Allhoff EP, König W (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58:121–129
Balistreri CR, Carruba G, Calabrò M, Campisi I, Di Carlo D, Lio D, Colonna-Romano G, Candore G, Caruso C (2009) CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann NY Acad Sci (in press)
Damber JE, Aus G (2008) Prostate cancer. Lancet 371:1710–1721
Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu F-C, Dimitrov L, Chang B, Turner AR, Liu W, Adami H-O, Suh E, Moore JH, Zheng SL, Isaacs WB, Trent JM, Groënberg H (2005) The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14:2563–2568
Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O’Neill LA (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78–83
Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S (2002) Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420:324–329
Miyaishi O, Ando F, Matsuzawa K, Kanawa R, Isobe K (2000) Cancer incidence in old age. Mech Ageing Dev 117:47–55
Stanta G, Campagner L, Cavallieri F, Giarelli L (1997) Cancer of the oldest old: what we have learned from autopsy studies. Clin Geriatr Med 13:55–68
Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C (2007) Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 128:83–91
Capri M, Salvioli S, Monti D, Caruso C, Candore G, Vasto S, Olivieri F, Marchegiani F, Sansoni P, Baggio G, Mari D, Passarino G, De Benedictis G, Franceschi C (2008) Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp Gerontol 43:53–60
Di Bona D, Vasto S, Capurso C, Christiansen L, Deiana L, Franceschi C, Hurme M, Mocchegiani E, Rea M, Lio D, Candore G, Caruso C (2009) Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev 8:36–42
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Imyanitov EN (2008) Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. Mech Ageing Dev 130:122–127
van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE, Westendorp RG, Long Life study group (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 40:11–15
Sardana G, Dowell B, Diamandis EP (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54(12):1951–1960
Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C (2007) Alzheimer’s disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8:1735–1745
Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, Listì F, Vasto S, Caruso C (2007) Pharmacogenomics: a tool to prevent and cure coronary heart disease. Curr Pharm Des 13:3726–3734
Sooriakumaran P, Kaba R (2005) The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review. Int J Surg 3:278–285
Puppo F, Murdaca G, Ghio M, Indiveri F (2005) Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 4:537–541
Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR (2003) A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63:8360–8365
Wang RF Y, Miyahara Y, Wang HY (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27:181–189
Acknowledgments
This work was supported by the Italian Ministry of Health grant (Molecular mechanisms of stem cancer cell survival control) to G. Carruba and C. Caruso and by Ministry of Education, University and Research (ex60%)grant to G. Candore and C. Caruso. The ‘‘Immunosenesence Research Group’’ coordinated by Prof. C. Caruso in association with ARNAS Experimental Oncology was amplified thanks to a joint contract.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Symposium in Writing on “Impact of Ageing on Cancer Immunity and Immunotherapy”.
Rights and permissions
About this article
Cite this article
Caruso, C., Balistreri, C.R., Candore, G. et al. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother 58, 1919–1933 (2009). https://doi.org/10.1007/s00262-009-0658-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-009-0658-y